Introduction
Anaplastic large cell lymphoma (ALCL) is an aggressive form of non-Hodgkin lymphoma often characterized by the chromosomal translocation t(2;5)(p23;q35). This translocation results in the expression of the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein (Morris et al., 1994) . Although the expression of ALK is usually confined to neonatal brain tissue (Iwahara et al., 1997) , the translocation places the gene under the regulation of the NPM promoter, which is abundantly and ubiquitously expressed. Furthermore, the dimerization of the fusion protein mediated by the oligomerization domain of NPM (Bischof et al., 1997) leads to its autophosphorylation and constitutive activation (Amin and Lai, 2007; Palmer et al., 2009) . NPM-ALK activates diverse growth factor signaling pathways including the JAK/STAT (Zamo et al., 2002) , the PI3K/AKT (Slupianek et al., 2001 ) and the PLCg pathways (Bai et al., 1998) . However, the cellular mechanisms utilized by NPM-ALK to induce oncogenesis have not been completely characterized.
To identify novel signaling proteins regulated by NPM-ALK, we carried out phosphoproteomic studies of t(2;5) þ cell lines using the approach outlined previously (Rush et al., 2005) . Our studies provide evidence that GSK3b is a novel NPM-ALK-regulated protein. GSK3b is a serine/threonine kinase that is constitutively active in resting cells Jope and Johnson, 2004) . Upon growth factor signaling, GSK3b is phosphorylated at serine-9, which inhibits its ability to target key substrates for proteasomal degradation. The accumulation of substrates of GSK3b such as CDC25A and Mcl-1 that regulate the cell cycle and apoptosis contributes to the enhanced proliferative capacity of tumor cells (Jinno et al., 1994; Diehl et al., 1997; Zhao et al., 2007; Kang et al., 2008) . Here, we show that serine-9 phosphorylation of GSK3b is dependent on NPM-ALK kinase activity and the PI3K/AKT pathway. We provide evidence that NPM-ALK results in stabilization of Mcl-1 and CDC25A through GSK3b inhibition, which in turn enhances cell viability, proliferation and oncogenic potential. Furthermore, tissue biopsies of ALK þ ALCLs express pS 9 -glycogen synthase kinase 3 beta (GSK3b) as well as CDC25A, providing additional support for its functional significance in ALK þ ALCLs.
Results and discussion
Given the oncogenic role of constitutively active NPM-ALK tyrosine kinase in ALK þ ALCL, we hypothesized that NPM-ALK-expressing cell lines would exhibit a phosphoproteomic signature that would reflect the signaling cascade regulated by the oncogene. To gain insight into these signaling pathways and to identify novel regulators of NPM-ALK-induced oncogenesis, we used a phosphoproteomic approach (Rush et al., 2005) to evaluate the tyrosine phosphorylated proteins in the NPM-ALK-expressing SUPM2 cell line. SUPM2 cell lysates were subjected to phosphopeptide enrichment using phosphotyrosine-specific antibodies, followed by tandem mass spectrometry. NPM-ALK-derived phosphotyrosine peptides in addition to numerous other phosphorylated proteins were identified (data not shown). Among this list was an eleven amino-acid tryptic peptide corresponding to GSK3b protein phosphorylated at Y216 (Figures 1a and b) . Of note, this phosphotyrosine peptide has been identified in a similar study contributing to the confidence of this candidate protein (Boccalatte et al., 2009) . On the basis of the known role of GSK3b in cellular signaling (Jope and Johnson, 2004) , we hypothesized that GSK3b may mediate the oncogenic properties of NPM-ALK. As GSK3b activity is known to be regulated by growth factor signaling through serine 9 phosphorylation, we hypothesized that NPM-ALK regulates the serine phosphorylation of GSK3b and inhibits its activity.
In order to determine whether serine phosphorylation of GSK3b is NPM-ALK dependent, we utilized a small molecule (Compound 15) to inhibit ALK kinase (Ott et al., 2010) . Treatment of SU-DHL-1 cells with the ALK inhibitor for 2 and 6 h resulted in a marked decrease in the levels of phosphorylated NPM-ALK (Y1604), but not total NPM-ALK (Figure 1c ). There was a marked decrease of pS 9 -GSK3b in both a doseand time-dependent manner, whereas total GSK3b levels remained unaffected. After 6 h of 300 nM ALK inhibitor treatment, only 34%-of the serine phosphorylated GSK3b remained. Three additional ALCL-derived cell lines (DEL, Karpas 299 and SUPM2) were treated with 300 nM ALK inhibitor for 6 h (Figure 1d) , and similar to the effect observed in SU-DHL-1 cells pS 9 -GSK3b was consistently reduced by ALK inhibition in all of the cell lines. Notably, in contrast to the marked decrease in ALK phosphorylation, the decrease in pS 9 -GSK3b was not complete. This may be partially explained by the existence of other kinases that phosphorylate GSK3b independent of NPM-ALK. Alternatively, the time points used may not be representative of the maximal loss of pS 9 -GSK3b. In addition, protein phosphatases that regulate pS 9 -GSK3b may be weakly active in the context of NPM-ALK. Similarly, 293T cells that were transiently transfected with vectors encoding the kinase-defective mutant (K210R) showed a 76% reduction in GSK3b serine phosphorylation, compared with those that expressed the wild-type NPM-ALK (Figure 1e) . Consistent with the previous observation, there was no effect on expression of total GSK3b protein levels. Next, we evaluated the effect of ALK knockdown using stable tetracycline-inducible small hairpin RNA (shRNA) targeting NPM-ALK in SU-DHL-1 cells (Ito et al., 2010) . Successful knockdown of NPM-ALK, which was observed after 4 days of tetracycline treatment, led to a marked decrease (79%) in pS 9 -GSK3b (Figure 1f ), whereas the total GSK3b protein levels remained unchanged. These data demonstrate that NPM-ALK kinase activity is required for the serine-9 phosphorylation of GSK3b.
Interrogation of the phosphoproteomic data identified several serine kinases that are known to phosphorylate GSK3b (data not shown). These included the PI3K, PKC and PKA kinases. As the PI3K/AKT pathway is known to be activated by NPM-ALK as well as responsible for GSK3b serine phosphorylation (Cross et al., 1995; Slupianek et al., 2001) , we hypothesized that the regulation of pS 9 -GSK3b by NPM-ALK is mediated by PI3K/AKT. We utilized a selective small molecule inhibitor against PI3K-d (CAL-101) (Herman et al., 2010) to determine the effect of PI3K/AKT inhibition on pS 9 -GSK3b in SU-DHL-1 cells. Exposure to CAL-101 for 24 h at increasing concentrations resulted in decreased phosphorylation of pS 9 -GSK3b and pS 473 -AKT in a dose-dependent manner ( Figure 2a ). Importantly, p-ALK was not affected by CAL-101-mediated inhibition of PI3K/ AKT. These data show that the PI3K/AKT pathway mediates the serine 9 GSK3b phosphorylation by NPM-ALK. However, this doesn't preclude the possibility that other pathways active in such as WNT (van Noort et al., 2002) or PLCg (Bai et al., 1998 ) also contribute to GSK3b phosphorylation.
The serine 9 phosphorylation of GSK3b results in inhibition of its kinase activity . As active GSK3b is known to target a variety of proteins for proteasomal degradation, we hypothesized that two known substrates of GSK3b, CDC25A and Mcl-1 would be deregulated in ALCL cells. We evaluated the expression of CDC25A in SU-DHL-1 cells after the inhibition of ALK at indicated time points, following release from double thymidine block synchronization (Bostock et al., 1971) (Figure 2b ). ALK inhibition resulted in significant reduction of CDC25A levels in a time-dependent manner, with only 30% of the protein remaining after 8 h. In contrast, CDC25A expression remained unchanged through the entire 8 h time period in the dimethyl sulfoxide (DMSO) control condition. These data suggest that NPM-ALK deregulates the normal cyclical expression of CDC25A and leads to stabilization and enhanced expression throughout the cell cycle (Jinno et al., 1994) . Similarly, the expression of Mcl-1 and CDC25A were analyzed in SU-DHL-1 cells in the presence of ALK inhibitor and/or proteasome inhibitor (MG132) after release from synchronization using double thymidine block. As shown in Figure 2c , inhibition of ALK resulted in a significant downregulation of Mcl-1 (47% of control) and CDC25A (14% of control), which was recoverable by simultaneous inhibition of the proteasome. These data suggest that NPM-ALK activity enhances the stability of Mcl-1 and CDC25A. Interestingly, MG132 treatment resulted in recovery of Mcl-1 and CDC25A levels that exceeded the expression in the DMSO control (120% and 358%, respectively), suggesting that NPM-ALK does not provide complete proteasomal protection for these proteins.
To determine the role of GSK3b in proteasomal degradation of Mcl-1, SU-DHL-1 cells were treated with Figure 1 Identification of GSK3b as NPM-ALK-regulated phosphoprotein (a) SU-DHL-1 (ALK þ ALCL) cells were subjected to PhosphoScan (Cell Signaling Technologies) enrichment and tandem mass spectrometry as previously described (Rush et al., 2005) . Representative mass spectrum of phosphopeptide from GSK3b is shown. Identified b and y ions are indicated. (b) The sequence and cleavage sites for the identified GSK3b phosphopeptide. (c) SU-DHL-1 cells were treated for 2 and 6 h with the ALK inhibitor (Compound 15, Cephalon Inc) at indicated doses in 1% fetal bovine serum media conditions. The synthesis and selectivity of the novel 7-amino-1,3,4,5-tetrahydrobenzoazepinone derivative selective ALK inhibitor (Compound 15) and its properties were described previously (Ott et al., 2010) . Cell lysates were resolved on SDS-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes. Western blot analysis of GSK3b, pS (Ito et al., 2010) . After 4 days of tetracycline treatment, cells were harvested and subjected to western blotting. Densitometry of pS 9 -GSK3b is indicated as relative to control.
the ALK inhibitor and/or a GSK3 inhibitor (inhibitor IX) for 6 h. As shown in Figure 2d , the decrease in Mcl-1 upon ALK inhibition was abrogated by GSK3 inhibition. Thus, NPM-ALK-mediated inhibition of GSK3b results in protection of Mcl-1 from proteasomal degradation. These data provide evidence for the role of GSK3b in enhancing the stability of Mcl-1 in NPM-ALK-expressing cells. As Mcl-1 is a known antiapoptotic protein (Maurer et al., 2006) , we asked whether NPM-ALK confers resistance to apoptosis by its inhibition of GSK3b. Western blot analyses were performed on SU-DHL-1 and SUPM2 cell lysates to evaluate poly (ADP-ribose) polymerase (PARP) cleavage as a surrogate marker for apoptosis (Boulares et al., 1999) . Cells treated with the GSK3b inhibitor IX alone resulted in no change in PARP cleavage, whereas ALK inhibition greatly reduced ALK phosphorylation and increased the cleavage of PARP (Figure 2e) . Interestingly, when both enzymes were inhibited, PARP cleavage was significantly reduced compared with the ALK inhibitor alone. These data indicate that NPM-ALK leads to inhibition of GSK3b, which provide protection against apoptosis.
To determine whether GSK3b is a key mediator of NPM-ALK-induced oncogenesis, we assessed the effect of inhibitor IX on the cell viability of two ALCLderived cell lines. An effective dose of 100 nM of Inhibitor IX was selected because it represents a concentration well above the IC 50 (inhibitory concentration) for GSK3b but below the IC 50 for other serine/ threonine kinases (Meijer et al., 2003) . As expected, the ALK inhibitor (100 nM) resulted in a dramatic reduction of cell viability as determined by WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay (Figure 3a) to approximately 35% of control in both cell lines. Treatment of ALCLderived cell lines, SU-DHL-1 and SUPM2 with the GSK3b Inhibitor IX (100 nM) did not affect viability after 24 h. Notably, exposure to both compounds simultaneously (dual) resulted in a viability of 55% and 47% compared with control in SU-DHL-1 and SUPM2 cells, respectively. This represents a significant recovery of viability compared with ALK inhibition (Po0.01). Importantly, Jurkat cells (ALK-negative T-lymphoblastic leukemia) were not responsive to either the inhibitor IX or the ALK inhibitor, and there was no To address the role of GSK3b in oncogenic potential of ALCL cells, Karpas 299 cells were treated with the ALK inhibitor and inhibitor IX for 6 h before seeding into methylcellulose media. After 14 days, colonies were stained and enumerated (Figure 3c ). Whereas inhibition of ALK led to a significant reduction of the number of colonies compared with control (51%), dual inhibition of both GSK3b and ALK caused a recovery in the number of colonies (79% compared with DMSO). We verified that 6 h pre-treatment did not affect viability before seeding into the methylcellulose media by trypan blue staining. This showed that the same number of viable cells was used for all conditions that were evaluated (Figure 3d) .
To further evaluate the role of GSK3b in NPM-ALKmediated oncogenesis, stable GSK3b knockdown cell lines were created by lentiviral transfection of shRNA targeted against GSK3b (Figure 3e ) in two ALCLderived cell lines. SU-DHL-1 and Karpas 299 cells stably expressing scramble or shGSK3b vectors were subjected to WST-1 assay following treatment with the ALK inhibitor (Figure 3f ). Both cell lines expressing scramble shRNA showed a decrease in viability upon ALK inhibition. In contrast, the cells with knockdown of GSK3b (shGSK3b) were resistant to the growth inhibitory effect of ALK inhibition. Similarly, cells expressing scramble shRNA displayed a signification reduction in number of colonies following ALK inhibition, whereas those with knockdown of GSK3b (shGSK3b) were resistant to ALK inhibition and showed more colonies (Figure 3g ). These data support the hypothesis that NPM-ALK-mediated phosphorylation of GSK3b promotes proliferation and oncogenic transformation. It is of interest to note that the rescue mediated by inhibition of GSK3b was not complete This may be because of the presence of several GSK3b-independent signaling pathways that are regulated by NPM-ALK such as JAK/STAT or ERK (Ruchatz et al., 2003; Marzec et al., 2006; Lim et al., 2009 ). This idea is also evident in the observation that pS 9 -GSK3b was not completely abolished by ALK inhibition (Figure 1c ), yet a dramatic decrease in cell viability was observed.
Immunohistochemistry (IHC) was performed on 16 ALK-positive ALCL (ALK þ ALCL) tissue biopsies and 16 ALK-negative ALCL (ALK-ALCL) tissue biopsies. ALK þ ALCL samples showed strong staining for ALK in both the cytoplasm and nucleus of neoplastic cells (Figure 4a ), whereas ALK-ALCL samples showed no expression of ALK (Figure 4e) . A total of 14 of the 16 ALK þ ALCL samples showed strong expression of pS 9 -GSK3b in the neoplastic cells with weak expression in adjacent endothelial cells (Figures 4b and d) . Additionally, 13 out of 16 ALK þ ALCL cases also showed expression of CDC25A, highlighting the nuclear membranes of the (Figure 4c ). Reactive lymphocytes did not express significant levels of pS 9 -GSK3b (Figure 4b ) or CDC25A (Figure 4c ). Using w-squared distribution to test whether the observed distribution is statistically different from the expected randomized distribution, we found that the ALK þ ALCL cases displayed a significant correlation of pS 9 -GSK3b and CDC25A expression (Po0.001) (Figure 4d ). In contrast, only 5 out of 16 of the ALK-ALCL cases showed expression of pS 9 -GSK3b in the neoplastic cells whereas the infiltrating neutrophils showed strong expression (Figures 4f  and h ). CDC25A expression in ALK-ALCL was present in 11 out of 16 cases. Figure 4g shows a representative case of ALK-ALCL lacking CDC25A expression. In contrast to the ALK þ ALCL cases, the ALK-ALCL cases displayed a lack of significant correlation of pS 9 -GSK3b and CDC25A expression distribution (Po0.2) (Figure 4h ). Reactive tonsillar tissues demonstrated weak expression of pS 9 -GSK3b in epithelial cells and scattered interfollicular activated T-lymphocytes (Figure 4i ). CDC25A expression was strongly expressed in the epithelial cells and in scattered interfollicular activated T-lymphocytes (Figure 4j ). These findings confirm the presence of the inhibited form of GSK3b and the accumulation of one of its downstream substrates in human ALCL tumor samples. Overexpression of CDC25A transcript has been observed in various lymphomas including ALK þ ALCLs (Fernandez-Vidal et al., 2009), however its expression in ALCL tumor tissue samples using IHC has not been reported previously.
In conclusion, our data show that NPM-ALK regulates the inhibitory serine phosphorylation of GSK3b in ALCL cells, providing a growth advantage and the maintenance of a proliferative phenotype. Our studies uncover a novel mechanism of NPM-ALKmediated oncogenesis. Detailed elucidation of such deregulated signaling events may be exploited in the design of targeted and combinatorial therapeutic strategies for the treatment of ALK-driven neoplasia.
Materials and methods
Cell lines and inhibitors SU-DHL-1, DEL, Karpas299 and SUPM2 cells were cultured in Roswell Park Memorial Institute medium 1640 þ 10% fetal bovine serum. 293T cells were cultured in DMEM þ 10% fetal bovine serum. All cells were maintained in humidified incubators containing 5% CO 2 . SU-DHL-1 cells stably expressing tetracycline-inducible shRNA targeting ALK were generated as previously described (Ito et al., 2010) . Transient transfections were done with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Stable GSK3b knockdown SU-DHL-1 and Karpas299 cells were generated by lentiviral transfection with MISSION shRNA sequence: 5 0 -CCGGCCCAAATGTC AAACTACCAAACTCGAGTTTGGTAGTTTGACATTTG GGTTTTT-3 0 (Sigma-Aldrich, St Louis, MO, USA). The 7-amino-1,3,4,5-tetrahydrobenzoazepinone derivative selective ALK inhibitor (Compound 15, Cephalon, Inc, Frazer, PA, USA) was previously described (Ott et al., 2010) . CAL-101 was acquired from Chemietek (Indianapolis, IN, USA). MG132 was acquired from Sigma-Aldrich. GSK3 Inhibitor IX was acquired from Calbiochem (San Diego, CA, USA). All compounds were dissolved in DMSO.
Phosphoproteomics SU-DHL-1 cells were lysed and proteins were trypsinized to produce peptides of manageable length for mass spectrometry analysis. Phosphotyrosine containing peptides were purified using the PhosphoScan kit (Cell Signaling Technologies, Danvers, MA, USA) and subjected to tandem mass spectrometry for protein identification (Rush et al., 2005) .
Western blotting and antibodies
Cell lysates were resolved on 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Antibodies used were: GSK3b, pS 9 -GSK3b, p-ALK (Y1604), Mcl-1, AKT, p-AKT (S473), PARP (rabbit, 1:1000, Cell Signaling), ALK (mouse, 1:1000, Invitrogen) and CDC25A (mouse, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
WST-1, colony formation and flow cytometry Cell proliferation and viability was assessed by WST-1 assay as per manufacturer's protocol (Roche Applied Science, Indianapolis, IN, USA). Colony formation assay was performed with MethoCult methylcellulose-based media as per manufacturer's protocol (Stemcell Technologies, Vancouver, British Columbia, Canada). After 14 days, colonies were stained with iodonitrotetrazolium chloride overnight and counted. Apoptosis and viability were assessed by flow cytometry following cell staining with Annexin V and PI (Vermes et al., 1995) .
Immunohistochemistry
Tissue samples were obtained from the archives of the Hematopathology Section, Department of Pathology, University of Michigan, with institutional approval (HUM00023256). IHC staining was conducted with the following antibodies: ALK (mouse, 1:100, Dako, Carpinteria, CA, USA), pS 9 -GSK3b (rabbit, 1:50, Cell Signaling Technology) and CDC25A (mouse, 1:500, Abcam, Cambridge, MA, USA).
